Literature DB >> 8717175

[Results of surgical therapy in renal hyperparathyroidism. Follow-up of 143 patients].

C Dotzenrath1, P E Goretzki, H D Roher.   

Abstract

Subtotal parathyroidectomy (SPTX) and total parathyroidectomy with autotransplantation (PTX and AT) are now equivalent and challenging surgical procedures, that now involve very low morbidity even in patients with serious secondary illness. In most cases, either brings about a significant amelioration of quality of life. It is rare for the illness to persist after such an operation. In most cases, this is the case only after an inadequate primary operation. An actual recurrence of the illness after at least 6 months is a much more serious problem and cannot usually be attributed to an inadequate operation. Our experience is based on operations performed in 143 patients and a follow-up of up to 8 years. In 68.7% of cases there was a noticeable improvement of bone pain immediately after the operation. This rate fell to 61.5% during subsequent years. Comparable results could not be achieved with any drug therapy. After SPTX the recurrence rate was 4.5%, and after PTX and AT, 5.5%. This is comparable to the results cited in the literature.

Entities:  

Mesh:

Year:  1996        PMID: 8717175     DOI: 10.1007/BF00184255

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  26 in total

1.  Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients.

Authors:  J F Henry; A Denizot; J Audiffret; G France
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

2.  Reoperation for secondary hyperparathyroidism in hemodialysis patients.

Authors:  C Dubost; M Kracht; P Assens; E Sarfati; J Zingraff; T Drüeke
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

3.  [Parathyroidectomy and autotransplantation in renal hyperparathyroidism. I. Morphologic studies for tissue selection].

Authors:  B Niederle; H Hörandner; R Roka; W Woloszczuk
Journal:  Langenbecks Arch Chir       Date:  1988

4.  Tertiary hyperparathyroidism after renal transplantation: operative indications.

Authors:  A M D'Alessandro; J S Melzer; J D Pirsch; H W Sollinger; M Kalayoglu; W B Vernon; F O Belzer; J R Starling
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

5.  Risk of adynamic bone disease in dialyzed patients.

Authors:  H H Malluche; M C Monier-Faugere
Journal:  Kidney Int Suppl       Date:  1992-10       Impact factor: 10.545

6.  Parathyroid surgery in patients with renal failure.

Authors:  F L Delmonico; C A Wang; N T Rubin; L S Fang; J T Herrin; A B Cosimi
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

7.  Secondary hyperparathyroidism: diagnosis of site of recurrence.

Authors:  D Casanova; E Sarfati; A De Francisco; J A Amado; M Arias; C Dubost
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

8.  Management of hypercalcemic hyperparathyroidism after renal transplantation.

Authors:  P J Garvin; M Castaneda; R Linderer; M Dickhans
Journal:  Arch Surg       Date:  1985-05

9.  Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up.

Authors:  M Palmer; H O Adami; R Bergström; S Jakobsson; G Akerström; S Ljunghall
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

10.  Surgical treatment of the parathyroid gland in patients with end-stage renal disease.

Authors:  M Albertucci; C M Zielinski; M Rothberg; A Sterpetti; R Klingman; J F Ronk
Journal:  Surg Gynecol Obstet       Date:  1988-07
View more
  2 in total

1.  A randomised study on a new cost-effective algorithm of quick intraoperative intact parathyroid hormone assay in secondary hyperparathyroidism.

Authors:  Marcin Barczyński; Stanisław Cichoń; Aleksander Konturek; Wojciech Cichoń
Journal:  Langenbecks Arch Surg       Date:  2005-02-15       Impact factor: 3.445

2.  European endocrine surgery in the 150-year history of Langenbeck's Archives of Surgery.

Authors:  Henning Dralle; A Machens
Journal:  Langenbecks Arch Surg       Date:  2010-03-09       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.